Targeted treatments for multiple myeloma: specific role of carfilzomib

Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly diagnosed setting, and Ph...

Full description

Saved in:
Bibliographic Details
Published inPharmacogenomics and personalized medicine Vol. 8; no. default; pp. 23 - 33
Main Authors Sugumar, Dhivya, Keller, Jesse, Vij, Ravi
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2015
Taylor & Francis Ltd
Dove Press
Dove Medical Press
Subjects
Analysis
Apoptosis
Cancer therapies
Care and treatment
Carfilzomib
Cytotoxicity
Dosage and administration
Drug dosages
Drug therapy
FDA approval
Inhibitor drugs
Kinases
Multiple myeloma
novel agents
Pharmaceuticals
Pharmacokinetics
proteasome inhibitor
Proteasomes
Proteins
relapsed and refractory
Review
Stem cells
targeted therapy
Transplants & implants
United States > US
targeted therapy
proteasome inhibitor
novel agents
relapsed and refractory
Online AccessGet full text

Cover

More Information
Summary:Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly diagnosed setting, and Phase III studies are entering their final analysis. Data continue to grow to support its use as both single-agent therapy and in combination with immunomodulatory and other novel agents. This review discusses the role of carfilzomib in the treatment of multiple myeloma. Its mechanism of action, pharmacokinetics, and role in clinical management will be reviewed.
ISSN:1178-7066
1178-7066
DOI:10.2147/PGPM.S39085